FDA Investigator Mike M Rashti

Mike M Rashti has conducted inspections on 213 sites in 9 countries as of 02 Dec 2011. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
213
Last Inspection Date:
02 Dec 2011
Investigator Role:
FDA Investigator
Redica ID:
100001100
Countries of Inspections:
United States of America, India, Ireland, Norway, Germany, Netherlands, France, United Kingdom of Great Britain and Northern Ireland, Canada
FDA Investigators that have inspected at least one site in common with Mike M Rashti:
Albert A Salvador, Amanda E Lewin, PhD, Anastasia I Offordile, Anastasia I Onuorah, Anastasia M Shields, Anita R Michael, Ann Marie Karnick, Ann Marie Montemurro, Ann Marie Schofield, Anne M Pilaro, Anthony A Charity, Anthony E Keller, RPh, Arindam Dasgupta, PhD, Audrey Thereset Uy, Benton M Ketron, Brian D Young, Brian S Keefer, Byungja E Marciante, Cara M Minelli, Ching Jeyg Chang, Christopher Bastedo, Craig D Zagata, Crayton Lee, Cynthia A Harris, MD, RN, Cynthia White, Daniel L Aisen, Debra J Bennett, Denise L Burosh, Derek S Dealy, Dr. Abhijit Raha, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Edward D Mcdonald, Erika M Wilkerson, Erin M Mcdowell, Frank J Marciniak, Gabrielle J Swain, Gajendiran Mahadevan, PhD, Gayle S Lawson, Geoffrey K Kilili, Hala L Selby, Jacqueline A O'shaughnessy, PhD, James E Frye, James P Mcevoy, Janete F Guardia, Jean M Kelahan, Jeannie R Mayberry, Jeen S Min, Joel D Martinez, John A Kadavil, PhD, Joseph L Despins, PhD, Joseph S Fanelli, Joseph T Dougherty, Judith A Paterson, Julianne C Mccullough, Julie D Bringger, Kara A Scheibner, PhD, Kelly I Anderson, Kelly N Kerr, Kendra A Biddick, Kendra L Brooks, Khin Mang U, MD, Kimberly A Dux, Kish Bolden, Kristina J Donohue, Kristina Mjoyce Pittman, Linda M Hoover, Lisa B Orr, LT John M Mastalski, LT Melanie M Mayor, USPHS, Marcelo O Mangalindan, Jr, Marcia Gelber, Margaret M Sands, Matthew R Noonan, Meena Bansal Gupta, PhD, Michael A Taylor, Michael F Skelly, PhD, Michael J Nerz, Michael Serrano, Michele Keane Moore, PhD, Michele M Falchek, Mohsen Rajabi Abhari, FDA, Nicola M Fenty Stewart, Nikisha M Bolden, Niraj R Mehta, PhD, Peter R Lenahan, Phillip M Pontikos, Regina T Brown, Rita F Larocca Mahoney, Robert B Shibuya, MD, Ronald A Stokes, Sam Pepe, Scott B Laufenberg, Shirley S Wen, Stanley Au, Stephanie Mangigian, MS/OSH, RN, Steven E Kane, Susan F Laska, MS, Susan Leibenhaut, MD, Tahseen Mirza, Tammy L Chavis, Tania E Vizcaino, Thomas E Friel, Thomas L Eggerman, Todd J Maushart, Vlada Matusovsky, Wayne T Smith, Xikui Chen (nmi), PhD, Yiying E Chen, Yiyue Zhang (nmi), PhD

Mike M Rashti's Documents

Publish Date Document Type Title
October, 2002 EIR Brian J. Czerniecki, M.D. - EIR, 2002-10-30
January, 2001 EIR Bellasorte, Joseph R. - EIR, 2001-01-25
October, 2002 FDA 483 Response Brian J. Czerniecki, M.D. - Form 483R, 2002-10-30
November, 2003 EIR Neal J. Meropol, M.d. - EIR, 2003-11-03
August, 2010 EIR Merck & Company, Inc. - EIR, 2010-08-20
May, 2010 FDA 483 Quintiles IMS Ireland Limited - Form 483, 2010-05-21
May, 2010 EIR Quintiles IMS Ireland Limited - EIR, 2010-05-21
June, 2003 EIR Barolat, Giancarlo, M.D. - EIR, 2003-06-10
March, 2010 FDA 483 AstraZeneca Pharmaceuticals LP - Form 483, 2010-03-31
July, 2003 EIR Radiant Research - EIR, 2003-07-08
February, 2001 EIR Premier Research - EIR, 2001-02-13
May, 2001 FDA 483 Response Avax Technologies - Form 483R, 2001-06-29
December, 2004 FDA 483 Albert Einstein Healthcare Network IRB - Form 483, 2004-12-16
April, 2003 FDA 483 Douglas B. Esberg, MD - Form 483, 2003-04-30
February, 2002 FDA 483 Henry, David Dr - Form 483, 2002-02-13
June, 2003 EIR Thomas Jefferson University Institutional Review Board - EIR, 2003-06-17
November, 2003 EIR Bilcare, Inc. - EIR, 2003-11-18
October, 2003 EIR GlaxoSmithKline - EIR, 2003-10-03
November, 2003 EIR Bioanalytical Solutions, LLC - EIR, 2003-11-18
October, 2001 FDA 483 Response Liacouras M.D., Chris A. - Form 483R, 2001-11-06
April, 2001 EIR Fraker, Douglas L. M.D. - EIR, 2001-04-05
April, 2001 FDA 483 Fraker, Douglas L. M.D. - Form 483, 2001-04-05
February, 2007 EIR Bioclinica, Inc. - EIR, 2007-02-20
August, 2000 EIR Metz,David C Md - EIR, 2000-08-17
January, 2010 FDA 483 Howard C. Herrmann, M.d. - Form 483, 2010-01-28
June, 2009 EIR Merck & Company, Inc. - EIR, 2009-06-05
January, 2000 FDA 483 Response James M. Wilson, MD - Form 483R, 2000-02-14
April, 2003 EIR Douglas B. Esberg, MD - EIR, 2003-04-30
October, 2010 EIR Bioclinica, Inc. - EIR, 2010-10-04
June, 2010 EIR ICON PLC - EIR, 2010-06-15
January, 2003 FDA 483 Hospital Of The University of Pennsylvania - Form 483, 2003-01-31
January, 2000 EIR James M. Wilson, MD - EIR, 2000-01-19
October, 2010 EIR Bioclinica, Inc. - EIR, 2010-10-29
January, 2000 FDA 483 University of Pennsylvania Health System - Form 483, 2000-01-19
January, 2010 EIR Howard C. Herrmann, M.d. - EIR, 2010-01-28
May, 2000 EIR Mitchell, Donald G. MD - EIR, 2000-05-17
October, 2001 EIR Liacouras M.D., Chris A. - EIR, 2001-10-11
January, 2003 EIR Garino, Jonathon M.D. - EIR, 2003-01-31
August, 2005 FDA 483 Response Alan R. Cohen, M.D. Chairman - Form 483R, 2005-08-10
October, 2005 EIR Siemens Medical Solutions USA, Inc - EIR, 2005-10-21
April, 2003 FDA 483 Response Douglas B. Esberg, MD - Form 483R, 2003-05-05
September, 2004 EIR Bioclinica, Inc. - EIR, 2007-12-31
November, 2005 EIR Glaxo Smith Kline (King Of Pruss - EIR, 2005-11-30
May, 2005 EIR Ball, Roberta R. DO - EIR, 2005-05-12
August, 2000 FDA 483 Depression Research Unit - Form 483, 2000-08-02
August, 2005 EIR Alan R. Cohen, M.D. Chairman - EIR, 2005-08-10
November, 2003 FDA 483 Neal J. Meropol, M.d. - Form 483, 2003-11-03
April, 2011 EIR Azur Pharma, Inc. - EIR, 2011-04-01
August, 2000 EIR Amsterdam, Jay - EIR, 2000-08-02
June, 2003 FDA 483 Barolat, Giancarlo, M.D. - Form 483, 2003-06-10
October, 2002 FDA 483 Brian J. Czerniecki, M.D. - Form 483, 2002-10-30
May, 2001 FDA 483 Avax Technologies - Form 483, 2001-05-25
October, 2001 FDA 483 Liacouras M.D., Chris A. - Form 483, 2001-10-11
November, 2010 EIR AstraZeneca Pharmaceuticals LP - EIR, 2010-11-10
February, 2002 EIR Henry, David Dr - EIR, 2002-02-13
August, 2000 FDA 483 University of Penn. Medical Center - Form 483, 2000-08-17
June, 2001 FDA 483 Berd,David A Md - Form 483, 2001-06-01
March, 2010 EIR ReSearch Pharmaceutical Services, Inc. - EIR, 2010-03-05
November, 2010 FDA 483 AstraZeneca Pharmaceuticals LP - Form 483, 2010-11-10
July, 2003 EIR Merck & Company, Inc. - EIR, 2003-07-30
March, 2010 EIR AstraZeneca Pharmaceuticals LP - EIR, 2010-03-31
January, 2003 FDA 483 Response Garino, Jonathon M.D. - Form 483R, 2003-02-04
July, 2006 EIR GlaxoSmithKline - EIR, 2006-07-27
May, 2001 EIR Avax Technologies - EIR, 2001-05-25
March, 2003 EIR eResearch Technology - EIR, 2003-03-25

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more